Actively Recruiting
BE.Amycon Biobank & Data Registry UZ Leuven: Human Body Material Collection and Data Collection for Patients With Amyloidosis
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-02-27
505
Participants Needed
2
Research Sites
17 weeks
Total Duration
On this page
Sponsors
U
Universitaire Ziekenhuizen KU Leuven
Lead Sponsor
F
Flemish institute of biotechnology (VIB)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are establishing the Belgian Amyloidosis Consortium (BE.AMYCON) to gather human body material (HBM) and clinical data from patients with amyloidosis. This observational study aims to improve understanding of amyloidosis by creating a biobank and a data registry that collects detailed patient information, disease characteristics, treatment plans, and outcomes over time. The study involves collecting and storing biological samples such as blood, urine, and tissue from patients with suspected or confirmed amyloidosis. Additionally, patient data including baseline demographics, disease presentation, treatments, and responses will be recorded. The biobank will store samples for up to 2 years, while the data registry will track patients for up to 10 years or until death, loss to follow-up, or withdrawal. Participants will provide informed consent and may contribute samples and clinical data during the study period. Researchers will monitor disease characteristics at diagnosis, treatment responses, survival times, and disease progression. This long-term collection of biological and clinical information aims to support future scientific research and improve treatment strategies for amyloidosis.
CONDITIONS
Brief Title
BE.Amycon Biobank & Data Registry UZ Leuven
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide consent and sign informed consent form
- Age 18 years or older
- Diagnosis of amyloidosis (suspected or confirmed, any subtype)
- For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis)
You will not qualify if you...
- Not willing to sign informed consent
- Not able to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants with suspected or confirmed amyloidosis have their biological samples and health data collected and stored for research purposes.
Visits for biological sample collection and data updates as needed
Duration - Up to 10 years
Participants are observed over time to track disease characteristics, treatment responses, and survival for up to 10 years.
Periodic visits or data collection depending on participant status
Trial Site Locations
Total: 2 locations
1
UZ Leuven Gasthuisberg - hematology
Leuven, Belgium, 3000
Actively Recruiting
2
UZ Leuven Gasthuisberg - cardiology
Leuven, Belgium
Actively Recruiting
Research Team
M
Michel Delforge
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here